A Japanese startup is conducting tests on a novel treatment for heart failure involving the catheter-based injection of induced pluripotent stem (iPS) cells designed to regenerate heart muscle. The aim is to offer a less invasive alternative to traditional open-heart surgery for patients suffering from damaged heart tissue. This method focuses on delivering the iPS-derived heart muscle cells directly to the affected area via a catheter, potentially minimizing recovery time and risks associated with major operations. Early trials are focused on assessing the safety and feasibility of the procedure. The company anticipates this technology could provide a new therapeutic option for a significant number of heart failure patients. Successful development would represent a major advancement in regenerative medicine and cardiac care. Further research and clinical trials are necessary before the treatment becomes widely available.